Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies.
The requirement of high doses of interferon (IFN) during therapy severely restrict its application. Thus a model using an Epstein-Barr virus (EBV) membrane antigen (MA) specific monoclonal antibody (MAb) was developed to assess the feasibility of coupling minimal amounts of IFN to a MAb and specifically delivering the IFN to the target cells. Coupled IFN was first shown to retain fully both its anti-viral and anti-proliferative properties when tested on human tumor cell lines QIMR-WIL (EBV-MA+) and the U-266 (EBV-MA-). A series of in vitro pulsing experiments demonstrated the specific targeting of both the anti-viral and anti-proliferative properties of IFN to the EBV-MA+ QIMR-WIL cells and not EBV-MA- cell lines.
Miescher-Granger
S
S
Hochkeppel
H K
HK
Braun
D G
DG
Alkan
S S
SS
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000956:Antigens, Viral / Q000276:immunology; D002294:Carcinoma, Squamous Cell; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000494:pharmacology; D007822:Laryngeal Neoplasms; D008574:Mengovirus / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D007370:Interferon Type I